BTG plc’s (BTG) “Neutral” Rating Reaffirmed at J P Morgan Chase & Co
J P Morgan Chase & Co reiterated their neutral rating on shares of BTG plc (LON:BTG) in a report published on Monday, Marketbeat reports.
Other analysts have also recently issued research reports about the company. Numis Securities Ltd reaffirmed a buy rating and set a GBX 900 ($12.13) target price on shares of BTG plc in a research report on Thursday, July 13th. Panmure Gordon dropped their target price on BTG plc from GBX 809 ($10.91) to GBX 793 ($10.69) and set a buy rating on the stock in a research report on Monday, May 22nd. Stifel Nicolaus reaffirmed a buy rating and set a GBX 800 ($10.79) target price on shares of BTG plc in a research report on Wednesday, August 30th. Finally, Shore Capital reaffirmed a not rated rating on shares of BTG plc in a research report on Thursday, July 13th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. BTG plc currently has a consensus rating of Buy and a consensus target price of GBX 780.33 ($10.52).
Shares of BTG plc (LON:BTG) opened at 665.50 on Monday. The company’s market capitalization is GBX 2.56 billion. BTG plc has a 52-week low of GBX 528.36 and a 52-week high of GBX 738.50. The company’s 50 day moving average price is GBX 672.19 and its 200 day moving average price is GBX 655.00.
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.